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Objectives: The wording of the Hungarian EQ-5D-3L and EQ-5D-5L descriptive systems differ a great deal. This study aimed to
(1) develop EQ-5D-3L and EQ-5D-5L value sets for Hungary from a common sample, and (2) compare how level wording
affected valuations.
Methods: In 2018 to 2019, 1000 respondents, representative of the Hungarian general population, completed composite time
trade-off tasks. Pooled heteroscedastic Tobit models were used to estimate value sets. Value set characteristics, single-level
transition utilities from adjacent corner health states, and mean transition utilities for all possible health states were
compared between the EQ-5D-3L and EQ-5D-5L.
Results: Health utilities ranged from -0.865 to 1 for the EQ-5D-3L and -0.848 to 1 for the EQ-5D-5L. The relative importance of
the 5 EQ-5D-5L dimensions was as follows: mobility, pain/discomfort, self-care, anxiety/depression, and usual activities.
A similar preference ranking was observed for the EQ-5D-3L with self-care being more important than pain/discomfort.
The EQ-5D-5L demonstrated lower ceiling effects (range of utilities for the mildest states: 0.900-0.958 [3L] vs 0.955-0.965
[5L]) and better consistency of mean transition utilities across the range of scale. Changing “confined to bed” (3L) to
“unable to walk” (5L) had a large positive impact on utilities. Smaller changes with more negative wording in the other
dimensions (eg, “very much anxious/feeling down a lot” [3L] vs “extremely anxious/depressed” [5L]) had a modest
negative impact on utilities.
Conclusion: This study developed value sets of the EQ-5D-3L and EQ-5D-5L for Hungary. Our findings contribute to the
understanding of how the wording of descriptive systems affects the estimates of utilities.
Keywords: EQ-5D, value set, composite time trade-off, QALY, Europe.
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Health technology assessment (HTA) is increasingly used to
inform resource allocation decisions and set priorities in health-
care in Hungary.1–4 National bodies within the Ministry of Human
Capacities and the Division for Health Technology Assessment at
the National Institute for Pharmacy and Nutrition publish guide-
lines and recommendations on conducting economic evaluations
of health interventions.5,6 In economic evaluations, health benefits
of an intervention are commonly expressed in quality-adjusted
life years (QALYs). The QALY is a widely used metric that cap-
tures both quantity (ie, survival) and quality (ie, utility) of life into
a single outcome. In Hungary, as in many other European coun-
tries,7 the EQ-5D descriptive system is on the list of preferred
measures to generate QALYs.8 Yet the absence of country-specific
value sets creates a barrier to its widespread use. In the past 2ss correspondence to: Fanni Rencz, MD, MSc, PhD, Department of Health Ec
y. Email: fanni.rencz@uni-corvinus.hu
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cess article under the CC BY-NC-ND license (http://creativecommons.org/licdecades, over 30 countries adopted the EQ-5D and developed
their own national value sets, enabling health policy decisions to
be based on the preferences of the population they are serving.9,10
The EQ-5D consists of a 5-item descriptive system and a self-
rating of overall health status on a 0-100 visual analog scale (EQ
VAS).11,12 The descriptive system has 2 versions suitable for adults,
the EQ-5D-3L and EQ-5D-5L (hereafter 3L and 5L) that both
measure health status on 5 dimensions: mobility (MO), self-care
(SC), usual activities (UA), pain/discomfort (PD), and anxiety/
depression (AD). In the 3L, each dimension has 3 levels of severity:
no problems, some/moderate problems, and confined to bed/un-
able to/extreme problems. For the 5L, the levels of severity are
expanded from 3 to 5: no problems, slight problems, moderate
problems, severe problems, and unable to/extreme problems.13
In most language versions, 2 important changes in wording of
the labels were introduced in the 5L version, which included usingonomics, Corvinus University of Budapest, 8 F}ovám tér, H-1093, Budapest,
Health Economics and Outcomes Research. Published by Elsevier Inc. This is an
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1236 VALUE IN HEALTH SEPTEMBER 2020“unable to walk” (5L) instead of “confined to bed” (3L) in the
descriptor of the most severe level of MO and standardizing the
middle levels to consistently use moderate (5L) in all di-
mensions.13 In addition to these changes, there are a number of
other differences between the Hungarian 3L and 5L versions that
affect both modifiers (eg, “very strong” [3L] vs “extreme” [5L]) and
descriptors (eg, “anxiety/feeling down” [3L] vs “anxiety/depres-
sion” [5L]) (see Appendix 1 in Supplemental Materials found at
https://doi.org/10.1016/j.jval.2020.03.019). Of the 15 matched la-
bels, the 5L uses words with more negative meaning in 8 cases,
whereas in 1 case a more severe problem appears in the 3L
descriptive system (ie, confined to bed).
Changes in wording of the EQ-5D may affect self-reporting of
health as well as health state valuations. Few parallel 3L and 5L
valuations have been carried out to date, and very limited evi-
dence is available on how changes in wording are reflected by
health state valuations.14–17 Therefore, the primary objective of
this study was to develop country-specific 3L and 5L value sets for
Hungary in a parallel valuation study. Secondarily, we aimed to
add to the literature in comparing the 3L and 5L value set char-
acteristics and analyzing the impact on utilities of wording dif-
ferences in the descriptive systems.Methods
Study Design
The study followed the criteria on the Checklist for Reporting
Valuation Studies of the EQ-5D.18 Data were collected via
computer-assisted personal interviews between May 2018 and
March 2019. The latest available version of EuroQol Valuation
Technique (EQ-VT) was used for this study (version 2.1).19 As a
methodological add-on to this protocol, a 3L valuation was
embedded in the design. In 2017, exactly the same valuation
framework was used in the United States.15,20,21 The study
received approval from the Scientific and Ethical Committee of the
Medical Research Council (reference no. 12006-2/2018/EKU) prior
to data collection. The target sample size was 1000 respondents
complying with the EuroQol Group’s valuation protocol.22
A non-probability quota sampling was used, and quotas were
set for age and sex according to the latest data reported by the
Hungarian Central Statistical Office.23 Inclusion criteria to the
study were (1) aged $18 years, (2) cognitive ability to read and
interpret questions, and (3) signed an informed consent form.
Participation in the study was voluntary and no remuneration was
provided. The interviewer team comprised 12 university students
studying economics or medicine and 1 of the principal in-
vestigators (see Appendix 2 in Supplemental Materials found at
https://doi.org/10.1016/j.jval.2020.03.019). Over the entire data
collection period, interviewer performance was monitored as a
part of the quality-control procedure developed by the EuroQol
Group.24 Details of the quality-control process are available in
Appendix 3 in Supplemental Materials found at https://doi.org/1
0.1016/j.jval.2020.03.019.
Health State Selection
A detailed description of 3L and 5L health state selections is
reported elsewhere15,25; however, it is briefly summarized here.
Two preference elicitation techniques, the composite time trade-
off (cTTO) and discrete choice experiment (DCE), were used. The
study design included a set of 30 (3L) health states divided into 10
cTTO blocks, 86 (5L) states divided into 10 cTTO blocks, and 196
pairs of 5L health states divided into 28 DCE blocks of 7 pairs.
Blocks as well as the order of health states within the blocks werepresented in a random order both for the cTTO and DCE. Each 3L
block contained 3 health states, and the pits state (33333)
appeared only in 1 of the 10 3L blocks. Each 5L block contained 10
health states including the pits state (55555) and 1 of the mildest
states (21111, 12111, 11211, 11121, or 11112). The DCE data collected
are not used in the present study. The interview tasks are pre-
sented in Appendix 2 in Supplemental Materials found at https://
doi.org/10.1016/j.jval.2020.03.019.
Composite Time Trade-Off
The cTTO approach combines conventional 10-year TTO for
health states considered better than dead (BTD) and lead-time
TTO (ie, 10 years in full heath followed by 10 years in a less than
healthy EQ-5D state) for health states considered worse than dead
(WTD).26 The cTTO utilities in this study ranged between -1 and 1
and were calculated according to the following formulas:
BTD responses: U¼ t=10
WTD responses: U¼ðt210Þ =10
where U is the utility and t is the number of years required in full
health.
Data Analysis
Descriptive statistics of the sample characteristics and cTTO
utilities were computed. No exclusions were made on the basis of
data quality, inconsistent responses (ie, a higher utility is attached
to a health state that is unambiguously more severe than another),
or non-trading (ie, assigning a utility of 1 to all health states). In
line with former valuation studies,27–29 5L cTTO responses flagged
by respondents in the feedback module were excluded. The effect
of the re-inclusion of these responses was assessed through a
sensitivity analysis. Data management and statistical analyses
were performed using STATA 13.0 (StataCorp LP, College Station,
TX) and R version 3.6.1 (The R Foundation for Statistical
Computing, Vienna, Austria). For all analyses, a P value ,.05 was
taken as statistically significant.
Modeling
The cTTO utilities for health states described by the 3L and 5L
were modeled separately. The dependent variable consisted of the
cTTO utility elicited. Main effects models including 10 and 20
dummy-coded parameters were applied both for the 3L and 5L,
respectively. A dummywas created for each level of health in respect
of each dimension, whereby level 1 was considered the reference
category. Both for 3L and 5L, we estimated 4 regression model ver-
sions: a pooled homoscedastic linear model (model 1); a pooled
heteroscedastic linear model (model 2); a pooled homoscedastic
Tobit model, left-censored at -1 (model 3); and a pooled hetero-
scedastic Tobit model, left-censored at -1 (model 4). All models were
estimated by maximum likelihood using the R package crch.30 To
account for the non-zero covariances between error terms clustered
within individuals (resulting from the repeated measure design), we
calculated robust standard errors using the clustered covariance
estimator incorporated to the R package sandwich.31
We considered multiple criteria for model selection, including
theoretical considerations (eg, the censored nature of cTTO utili-
ties and heteroscedasticity), the number of illogical and insignif-
icant parameters, and prediction accuracy (eg, Pearson’s and
Spearman’s correlations between predicted and observed utilities,
mean absolute error between predicted and observed utilities, and
proportion of health states with absolute prediction errors greater
Table 1. Characteristics of the sample.
Variables n % General
population
(%)24,51
Proportional
difference (%)
Sex
Female 533 53.3 53.1 0.2
Male 467 46.7 46.9 -0.2
Age (years)
18-24 100 10.0 10.0 0
25-34 152 15.2 15.2 0
35-44 194 19.4 19.5 -0.1
45-54 164 16.4 16.0 0.4
55-64 164 16.4 16.8 -0.4
65-74 130 13.0 13.0 0
751 96 9.6 9.5 0.1
Highest level
of education
Primary
school
or less
157 15.7 23.8 -8.1
Secondary
school*
502 50.2 55.0 -4.8
College/
university
degree
341 34.1 21.2 12.9
Place of
residence
Capital 348 34.8 17.9 16.9
Other town 454 45.4 52.6 -7.2
Village 198 19.8 29.5 -9.7
Geographical
region†
Central Hungary 533 53.3 30.4 22.9
Transdanubia 177 17.7 30.2 -12.5
Great Plain
and North
290 29.0 39.5 -10.5
Employment
status‡
Employed 620 62.0 53.1 8.9
Unemployed 10 1.0 3.1 -2.1
Retired 250 25.0 26.1 -1.1
Disability
pensioner
26 2.6 3.1 -0.5
Student 75 7.5 4.7 2.8
Homemaker/
housewife
19 1.9 1.0 0.9
Marital status
Single 239 23.9 18.5 5.4
Married 419 41.9 45.6 -3.7
Domestic
partnership
137 13.7 13.4 0.3
Divorced 83 8.3 11.1 -2.8
Widowed 122 12.2 11.4 -0.8
3L EQ VAS
(mean, SD)§
82.5 13.2 71.6 10.9
5L EQ VAS
(mean, SD)
81.6 13.8 N/A -
Self-perceived
health status
Excellent 135 13.5 N/A -
Very good 322 32.2 N/A -
Good 374 37.4 N/A -
Fair 154 15.4 N/A -
Poor 15 1.5 N/A -
Continued in the next column
Table 1. Continued
Variables n % General
population
(%)24,51
Proportional
difference (%)
History of
chronic illness
Yes 559 55.9 45.0 10.9
No 426 42.6 55.0 -12.4
Refused to
answer
15 1.5 N/A -
N/A indicates data not available; VAS, visual analog scale.
*With completed final exam or professional certificate.
†For the general population, figures represent the population aged 15 or over.
‡The sum of the general population is ,100% owing to an other category
accounting for 8.9%.
§Year of data collection was 2000.52
PREFERENCE-BASED ASSESSMENTS 1237than 0.05 and 0.1.) The preferred model was selected in favor of
accounting for the censored nature of cTTO utilities (ie, prefer-
ences of certain respondents may be even lower than -1),32 ac-
commodating heteroscedasticity stemming from the variation of
cTTO utilities between the mild and severe health states,33 and
reducing the number of illogical and insignificant parameters. The
intercept was interpreted as the utility decrement associated with
any deviation from full health. For the final value sets, it was
decided to constrain the intercept to be equal to 1 (full health) if it
was insignificant.
Comparing the Characteristics of the 3L and 5L Value Sets
Building on the methodology described by previous
studies,14,34 the 2 final value sets (model 4 [3L] and model 5 [5L])
were compared across a number of characteristics. For the ana-
lyses, levels 3 and 5 on the 5L were considered as matched levels
for levels 2 and 3 on the 3L.14 For example, 12111 (3L) and 13111
(5L) are matched health states.
Ceiling effects in the context of health state valuations were
examined by directly comparing the mildest 3L and 5L health
states.14 For the mildest and most severe health states, differences
in changes in single-level transition utilities between adjacent 3L,
5L, and matched 5L states were compared (ie, decrease in utility
from 11111 or increase from the pits state).34 Single-level transi-
tion utilities between adjacent 3L and adjacent 5L corner health
states (ie, health states described by an unhealthy level in 1
dimension, and no problems in all others) were computed. Then,
differences were calculated in single-level transition utilities be-
tween 3L and matched 5L health states.14,34
A Kernel density plot was created to visualize the modality of
the distributions of utilities for 3L (n = 243), 5L (n = 3125) and
matched 5L health states (n = 243). The 2 models were further
compared with respect to parameter estimates, order of dimen-
sion importance, range of utilities, and proportion of health states
valued as WTD. The agreement between matched utilities of the 2
models was examined using a Bland-Altman plot.35
Overall, mean transition utilities were computed for the 3L and
5L by averaging all single-level mean transition utilities of the 243
(3L) and 3125 (5L) health states.36,37 To estimate single-level mean
transition utilities for a health state (referred to here as the
baseline health state), all possible single-level movements to
adjacent from that given state were estimated. For example, all
possible single-level transitions from the baseline state of 44444
included 5 possible transitions to a better state (34444, 43444,
44344, 44434, and 44443) and 5 transitions to a worse state
Table 2. Parameter estimates of the Hungarian EQ-5D-3L value set.
Model 1
Pooled
linear
model, homoscedastic
Model 2
Pooled
linear model,
heteroscedastic
Model 3
Pooled
Tobit model,
homoscedastic
Model 4
Pooled
Tobit model,
heteroscedastic (value
set)‡
b SE P
value*
b SE P
value*
b SE P
value*
b SE P
value*
Intercept† 0.961 0.015 .012 0.979 0.008 .009 0.965 0.016 .028 0.980 0.008 .013
MO2 -0.026 0.014 .061 -0.022 0.008 .008 -0.025 0.014 .080 -0.022 0.008 .006
MO3 -0.596 0.026 ,.001 -0.619 0.028 ,.001 -0.611 0.027 ,.001 -0.648 0.031 ,.001
SC2 -0.064 0.017 ,.001 -0.051 0.009 ,.001 -0.064 0.017 ,.001 -0.051 0.009 ,.001
SC3 -0.318 0.020 ,.001 -0.347 0.020 ,.001 -0.328 0.021 ,.001 -0.355 0.022 ,.001
UA2 0.003 0.016 .852 -0.024 0.008 .004 0.003 0.016 .853 -0.025 0.008 .003
UA3 -0.229 0.019 ,.001 -0.243 0.019 ,.001 -0.234 0.019 ,.001 -0.246 0.021 ,.001
PD2 -0.093 0.014 ,.001 -0.081 0.010 ,.001 -0.093 0.015 ,.001 -0.080 0.010 ,.001
PD3 -0.322 0.019 ,.001 -0.334 0.018 ,.001 -0.328 0.020 ,.001 -0.338 0.019 ,.001
AD2 -0.069 0.018 ,.001 -0.077 0.011 ,.001 -0.070 0.018 ,.001 -0.078 0.011 ,.001
AD3 -0.249 0.019 ,.001 -0.257 0.019 ,.001 -0.253 0.020 ,.001 -0.258 0.020 ,.001
Illogical parameters 1 0 1 0
Insignificant
parameters (P $ .05)
2 0 2 0
MAE (predicted
vs observed)
0.034 0.033 0.035 0.036
Health states
.j0.05j, n (%)
7 of 30 (23.3) 4 of 30 (13.3) 4 of 30 (13.3) 5 of 30 (16.7)
Health states
.j0.10j, n (%)
1 of 30 (3.3) 2 of 30 (6.7) 2 of 30 (6.7) 2 of 30 (6.7)
Pearson’s correlation
(predicted vs observed)
0.995 0.994 0.995 0.994
Spearman’s correlation
(predicted vs observed)
0.990 0.993 0.991 0.992
Dimension importance MO. PD. SC. AD. UA MO. SC. PD. AD. UA MO. PD. SC. AD. UA MO. SC. PD. AD. UA
No. (%) of health
states WTD
53 (21.8) 58 (23.9) 54 (22.2) 63 (25.9)
U (11111) 0.961 0.979 0.965 0.980
U (22222) 0.712 0.724 0.716 0.724
U (33333) -0.753 -0.821 -0.789 -0.865
Mean utilities (SD) 0.307 (0.368) 0.294 (0.387) 0.297 (0.378) 0.280 (0.400)
Median utilities (IQR) 0.326 (0.547) 0.325 (0.578) 0.320 (0.565) 0.311 (0.601)
AD indicates anxiety/depression; IQR, interquartile range; MAE, mean absolute error; MO, mobility; SC, self-care; PD, pain/discomfort; SE, standard error; UA, usual
activities; WTD, worse than dead.
*P values indicate the incremental disutility from the preceding level.
†P values for the intercept refer to the difference between the intercept and 1.
‡Example for using the Hungarian EQ-5D-3L value set: the predicted utility value for state 12321 is 0.980-0-0.051-0.246-0.080-0 = 0.603.
1238 VALUE IN HEALTH SEPTEMBER 2020(54444, 45444, 44544, 44454, and 44445). The absolute differ-
ences in utilities between each single-level transition utility and
their baseline health state were calculated and averaged to obtain
a single mean transition utility for every baseline health state. In
total there were 1 620 (3L) and 25 000 (5L) single-level transitions,
respectively. Four separate analyses were carried out: (1) single-
level transitions for all 3L states, (2) single-level transitions for
all 5L states, (3) single-level transitions for all matched 5L states,
and (4) 2-level transitions for 5L states.14
The relationship between mean transition and baseline utilities
was estimated by using ordinary least squares regression with
standard errors adjusted for heteroscedasticity. All transition utilities
were plotted against baseline 3L or 5L utilities to illustrate theconsistency of transition utilities by misery scores (ie, the sum of the
levels across dimensions ranging from 5 to 15 [3L] or 25 [5L]).
Within the context of the QALY model, utilities are measured on an
interval scale, where the same change in health status is expected to
represent the same, irrespective of the part of the scale being
considered.38 Thus, in general, the more consistent the mean tran-
sition utilities on the entire scale, the better the instrument is.
Results
Respondent Characteristics
A total of 1000 respondents, representative of the Hungarian
general population for age and sex, were successfully interviewed.
PREFERENCE-BASED ASSESSMENTS 1239In total, 1177 potential respondents were approached (response
rate 85%). Reasons for interview failure are provided in Appendix
4 in Supplemental Materials found at https://doi.org/10.1016/j.
jval.2020.03.019.
The characteristics of the sample are summarized in Table 1.
The distribution of the sample in marital status, employment
status, and area of residence reasonably approximated that of the
general population. Higher-educated respondents and inhabitants
of Central Hungary were slightly overrepresented.
Data Characteristics
There were no missing responses for any valuation task
resulting in a total of 3000 (3L) and 10 000 (5L) cTTO responses
from 1000 respondents. A flowchart presenting an overview of the
results of the 5L quality-control process is provided in Appendix 3
in Supplemental Materials found at https://doi.org/10.1016/j.jval.2
020.03.019. Before the feedback module, a total of 196 (19.6%)
respondents had at least 1 inconsistent 5L response. In the feed-
back module, 634 cTTO responses were removed by 481 (48.1%)
respondents. The proportion of respondents with logical in-
consistencies was reduced to 70 (7.0%) after the feedback module.
Thus, data analysis included 9366 (5L) cTTO observations from
1000 respondents.
For the 3L, logical inconsistencies occurred in 13 (1.3%) of the
respondents. No feedback module was built into the EQ-VT for
reconsideration of 3L responses, thus we included all the 3000
(3L) responses in the data analysis. Distribution and summary
statistics of the observed cTTO utilities for the 3L and 5L are
presented in Appendices 5, 6, and 7 in Supplemental Materials
found at https://doi.org/10.1016/j.jval.2020.03.019.
EQ-5D-3L Value Set
The 3L model results are presented in Table 2. In model 1 (3L)
and model 3 (3L), the estimates for UA2 were both insignificant
and illogically ordered from UA1, and in addition the difference
between MO1 and MO2 was insignificant. In model 2 (3L) and
model 4 (3L), all coefficients were consistent with the monotonic
nature of the descriptive system and statistically significant from
the preceding level. In these 2 models, only 2 (6.7%) of the pre-
dicted 30 health state utilities differed from observed utilities by
more than 0.10. Model 4 (3L) was selected as the final value set on
the basis of considerations outlined in the Methods section, such
as handling left-censored data, accounting for heteroscedasticity
and logical ordering, and statistical significance of parameters.
EQ-5D-5L Value Set
The parameter estimates and prediction accuracy of the 5L
models are shown in Table 3. For all models, every coefficient was
consistent; however, UA5 and PD3 in model 1 (5L), UA5 in model 2
(5L), and PD3 in models 3 (5L) and 4 (5L) were insignificant. Model
4 (5L) produced a slight improvement in prediction accuracy. In
this model, utilities for 2 (2.3%) of 86 heath states differed by more
than 0.10 from their observed utilities. The parameter of the
intercept did not differ significantly from 1. A constrained version
of model 4 (5L) was selected as the final value set (model 5 [5L]).
Sensitivity analysis indicated no significant impact of exclusions
on parameter estimates.
Comparison of 3L and 5L Value Sets
A comparison of the matched regression parameters of the 2
value sets (model 4 [3L] vs model 5 [5L]) is presented in Appendix
8 in Supplemental Materials found at https://doi.org/10.1016/j.
jval.2020.03.019. The 3L parameter estimates were higher (less
negative) for all matched levels, with the exception of the mostsevere level of MO and the middle level of PD. A good concordance
was observed in the preference ranking of the 5 dimensions; MO
was consistently placed the most, while UA the least important
(Tables 2 and 3). The proportion of health states valued as WTD
was higher for the 3L (25.9% [3L] vs 21.7% [5L]). The 3L value set
demonstrated lower minimum utility compared with 5L (-0.865
[3L] vs -0.848 [5L]). The 5L demonstrated lower ceiling effects
(range of utilities for the mildest states: 0.900-0.958 [3L] vs 0.955-
0.965 [5L]) (Table 4).
Figure 1 depicts the Kernel density estimates of all attainable
3L, 5L, and matched 5L utilities. Distribution of the 5L was
unimodal, whereas the 3L had few clusters. A higher density of the
3L compared with 5L was demonstrated on both ends of the utility
scale. Of the 243 matched health states, 160 (65.8%) showed a
higher utility for the 3L, while 83 (34.2%) for the 5L. The Bland-
Altman plot (Fig. 2) indicated a good level of agreement be-
tween 3L and matched 5L utilities. Of the 81 matched pairs in
which the most severe level of MO was affected, 77 (95.1%) indi-
cated a lower utility for the 3L. Conversely, a higher 3L utility was
predicted in 156 (96.3%) of the other 162 health states.
Comparison of Transitions From 11111 and the Pits State
For the mildest health states, differences in single-level tran-
sition utilities from 11111 between 3L and unmatched 5L ranged
from 0.035 to 0.045 (see Appendix 9 in Supplemental Materials
found at https://doi.org/10.1016/j.jval.2020.03.019). The largest
difference between the 3L and matched 5L states was found for
MO: 0.022 (3L) versus 0.089 (5L). Unmatched differences in
single-level transition utilities from the pits state were consider-
ably larger for the 3L (range: -0.626 to -0.180) compared with 5L
(-0.192 to -0.059). Matched differences in single-level transition
utilities from pits between 3L and 5L health states were of similar
size for all dimensions with the exception of MO (“confined to
bed” [3L]: -0.626 vs “unable to walk” [5L]: -0.366).
Comparison of Transitions for Adjacent Corner States
Single-level transitions between adjacent corner states for
the 2 value sets are compared in Table 4. In all dimensions, the
largest differences in utilities occurred between levels 2 and 3
for the 3L and between levels 3 and 4 for the 5L with the
exception of MO (5L). The transition utilities well reflected the
divergence of wording between the 2 descriptive systems. The
largest difference was found for the most severe level of MO
(“confined to bed” [3L] vs “unable to walk” [5L]: 0.260). In all
but 1 matched middle or extreme level categories where the 5L
uses a more negative word (middle levels of MO, SC, UA, and
AD, and the extreme levels of PD and AD), differences between
levels were larger for the 5L. Changing the descriptor “feeling
down” (3L) to “depressed” (5L) parallel to changing the adjec-
tives “a little” (3L) and “a lot” (3L) to “moderately” (5L) and
“extremely” (5L), respectively, had a small negative impact on
single-level transition utilities (matched middle level -0.015 and
extreme level -0.067).
Comparison of Mean Transition Utilities
Appendix 10 in Supplemental Materials found at https://doi.
org/10.1016/j.jval.2020.03.019 displays the mean single-level 3L,
5L, matched 5L and 2-level transition utilities as a function of their
respective baseline utilities. Mean 6 SD single-level transition
utility of all possible health states was substantially higher for the
3L (0.185 6 0.049) compared with the 5L (0.092 6 0.021). Mean
single-level transition utilities were larger by, on average, 0.097
(3L) and 0.043 (5L) for every 1-point decrease in utilities
(P,.0001). Likewise, a significant negative relationship was found
Table 3. Parameter estimates of the Hungarian EQ-5D-5L value set.
Model 1
Pooled linear model,
homoscedastic
Model 2
Pooled linear model,
heteroscedastic
b SE P value* b SE P value*
Intercept† 1.002 0.014 .912 1.009 0.007 .229
MO2 -0.051 0.013 ,.001 -0.047 0.008 ,.001
MO3 -0.113 0.014 ,.001 -0.117 0.014 ,.001
MO4 -0.289 0.014 ,.001 -0.282 0.014 ,.001
MO5 -0.434 0.014 ,.001 -0.427 0.014 ,.001
SC2 -0.041 0.012 ,.001 -0.053 0.007 ,.001
SC3 -0.079 0.014 .013 -0.089 0.010 .001
SC4 -0.252 0.018 ,.001 -0.243 0.016 ,.001
SC5 -0.313 0.012 ,.001 -0.326 0.014 ,.001
UA2 -0.037 0.013 .004 -0.043 0.007 ,.001
UA3 -0.081 0.017 .005 -0.087 0.013 .001
UA4 -0.209 0.013 ,.001 -0.222 0.012 ,.001
UA5 -0.228 0.012 .212 -0.240 0.013 .315
PD2 -0.057 0.011 ,.001 -0.051 0.007 ,.001
PD3 -0.084 0.014 .117 -0.085 0.014 .028
PD4 -0.281 0.015 ,.001 -0.284 0.014 ,.001
PD5 -0.377 0.014 ,.001 -0.398 0.017 ,.001
AD2 -0.043 0.014 .002 -0.045 0.006 ,.001
AD3 -0.122 0.018 ,.001 -0.112 0.014 ,.001
AD4 -0.282 0.014 ,.001 -0.268 0.013 ,.001
AD5 -0.316 0.013 .028 -0.315 0.012 ,.001
Illogical parameters 0 0
Insignificant parameters (P $ .05) 2 1
MAE (predicted vs observed) 0.033 0.032
Health states .j0.05j, n (%) 20 of 86 (23.3) 18 of 86 (20.9)
Health states .j0.10j, n (%) 4 of 86 (4.7) 3 of 86 (3.5)
Pearson’s correlation (predicted vs observed) 0.994 0.994
Spearman’s correlation (predicted vs observed) 0.990 0.991
Dimension importance MO . PD . AD . SC . UA MO . PD . SC . AD . UA
No. (%) of health states WTD 592 (18.9) 606 (19.4)
U (11111) 1.002 1.009
U (33333) 0.523 0.519
U (55555) -0.666 -0.697
Mean utilities (SD) 0.264 (0.294) 0.262 (0.296)
Median utilities (IQR) 0.275 (0.415) 0.275 (0.420)
AD indicates anxiety/depression; IQR, interquartile range; MAE, mean absolute error; MO, mobility; PD, pain/discomfort; SC, self-care; SE, standard error; UA, usual
activities; WTD, worse than dead.
*P values indicate the incremental disutility from the preceding level.
†P values for the intercept represent the difference between the intercept and 1.
‡Example for using the Hungarian EQ-5D-5L value set: the predicted utility value for state 12345 is 1-0-0.045-0.085-0.288-0.340 = 0.242.
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Table 3. Continued
Model 3
Pooled Tobit model, homoscedastic
Model 4
Pooled Tobit model,
heteroscedastic
Model 5
Pooled Tobit model,
heteroscedastic, constrained (value
set)‡
b SE P value* b SE P value* b SE P value*
1.003 0.014 .827 1.005 0.007 .498 1.000 - -
-0.045 0.013 ,.001 -0.038 0.008 ,.001 -0.035 0.006 ,.001
-0.100 0.014 ,.001 -0.090 0.014 ,.001 -0.089 0.013 ,.001
-0.278 0.014 ,.001 -0.264 0.014 ,.001 -0.263 0.014 ,.001
-0.445 0.014 ,.001 -0.455 0.015 ,.001 -0.455 0.015 ,.001
-0.040 0.012 .001 -0.048 0.007 ,.001 -0.045 0.005 ,.001
-0.078 0.015 .016 -0.088 0.010 ,.001 -0.089 0.010 ,.001
-0.251 0.018 ,.001 -0.242 0.016 ,.001 -0.241 0.016 ,.001
-0.337 0.013 ,.001 -0.366 0.016 ,.001 -0.366 0.016 ,.001
-0.034 0.013 .007 -0.038 0.007 ,.001 -0.035 0.004 ,.001
-0.081 0.017 .004 -0.086 0.013 ,.001 -0.085 0.013 ,.001
-0.208 0.013 ,.001 -0.219 0.012 ,.001 -0.217 0.012 ,.001
-0.250 0.012 .008 -0.277 0.014 .002 -0.276 0.014 .001
-0.053 0.011 ,.001 -0.046 0.006 ,.001 -0.043 0.005 ,.001
-0.082 0.014 .099 -0.073 0.014 .084 -0.073 0.014 .038
-0.286 0.015 ,.001 -0.287 0.014 ,.001 -0.288 0.014 ,.001
-0.391 0.015 ,.001 -0.413 0.018 ,.001 -0.411 0.018 ,.001
-0.042 0.014 .003 -0.042 0.006 ,.001 -0.040 0.005 ,.001
-0.115 0.019 ,.001 -0.095 0.014 ,.001 -0.093 0.014 ,.001
-0.281 0.014 ,.001 -0.262 0.013 ,.001 -0.261 0.013 ,.001
-0.329 0.013 .003 -0.341 0.013 ,.001 -0.340 0.013 ,.001
0 0 0
1 1 0
0.032 0.032 0.032
16 of 86 (18.6) 17 of 86 (19.8) 17 of 86 (19.8)
3 of 86 (3.5) 2 of 86 (2.3) 2 of 86 (2.3)
0.994 0.993 0.993
0.991 0.993 0.993
MO . PD . SC . AD . UA MO . PD . SC . AD . UA MO . PD . SC . AD . UA
623 (19.9) 676 (21.6) 677 (21.7)
1.003 1.005 1.000
0.513 0.573 0.571
-0.703 -0.847 -0.848
0.256 (0.296) 0.251 (0.317) 0.251 (0.318)
0.269 (0.420) 0.266 (0.448) 0.265 (0.449)
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Table 4. Comparison of adjacent corner health states for changes.
Exact wording in
Hungarian
translated to
English
3L
state
3L
utility
Diff. [A] Exact
wording in
Hungarian
translated
to English
5L
state
5L
utility
Diff. [B] Diff. [C] More
negative
word
Diff.
[A]-[C]*
MO No problems in
walking about
11111 1.000 No problems in
walking about
11111 1.000 Id.
Slight problems in
walking about
21111 0.965 0.035
Some problems in
walking about
21111 0.958 0.022 Moderate problems
in walking about
31111 0.911 0.054 0.089 5L -0.067
Severe problems in
walking about
41111 0.737 0.174
Confined to bed 31111 0.332 0.626 Unable to walk
about
51111 0.545 0.192 0.366 3L 0.260
SC No problems with
self-care
11111 1.000 No problems
washing or
dressing
11111 1.000 Id.†
Slight problems
washing or dressing
12111 0.955 0.045
Some problems with
washing or dressing
12111 0.929 0.051 Moderate problems
washing or dressing
13111 0.911 0.044 0.089 5L -0.038
Severe problems
washing or dressing
14111 0.759 0.152
Unable to wash or
dress
13111 0.625 0.304 Unable to wash or
dress
15111 0.634 0.125 0.277 Id. 0.027
UA No problems
performing usual
activities
11111 1.000 No problems doing
usual activities
11111 1.000 Id.
Slight problems
doing usual activities
11211 0.965 0.035
Some problems with
performing usual
activities
11211 0.922 0.058 Moderate problems
doing usual activities
11311 0.915 0.050 0.085 5L -0.027
Severe problems
doing usual activities
11411 0.783 0.132
Unable to perform
usual activities
11311 0.734 0.188 Unable to do usual
activities
11511 0.724 0.059 0.191 Id. -0.003
PD No pain or
discomfort
11111 1.000 No pain or
discomfort
11111 1.000 Id.
Slight pain or
discomfort
11121 0.957 0.043
Moderate pain or a
little discomfort
11121 0.900 0.080 Moderate pain or
moderate
discomfort
11131 0.927 0.030 0.073 5L 0.007
Severe pain or
discomfort
11141 0.712 0.215
Very strong pain or
very large
discomfort
11131 0.642 0.258 Extreme pain or
extreme discomfort
11151 0.589 0.123 0.338 5L -0.080
AD Not anxious or not
feeling down
11111 1.000 Not anxious or
depressed
11111 1.000 5L
Slightly anxious or
depressed
11112 0.960 0.040
Moderately anxious
or feeling down a
little
11112 0.902 0.078 Moderately anxious
or moderately
depressed
11113 0.907 0.053 0.093 5L -0.015
Severely anxious or
depressed
11114 0.739 0.168
continued on next page
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Table 4. Continued
Exact wording in
Hungarian
translated to
English
3L
state
3L
utility
Diff. [A] Exact
wording in
Hungarian
translated
to English
5L
state
5L
utility
Diff. [B] Diff. [C] More
negative
word
Diff.
[A]-[C]*
Very much anxious
or feeling down a
lot
11113 0.722 0.180 Extremely anxious
or extremely
depressed
11115 0.660 0.079 0.247 5L -0.067
Note. [A] difference from less severe adjacent 3L state; [B] difference from less severe adjacent 5L state; [C] difference between 3L and matched 5L states. Bold words
indicate a change in the strength of adjective. Bold and underlined words indicate a change of a descriptor (ie, noun/verb) that determines the label/dimension.
AD indicates anxiety/depression; 5L, 5-level; MO, mobility; PD, pain/discomfort; SC, self-care; 3L, 3-level; UA, usual activities.
*Negative numbers indicate that differences between levels are larger for the 5L.
†Can be considered identical.
PREFERENCE-BASED ASSESSMENTS 1243between baseline 5L utilities and single-level transitions
computed for matched 5L health states and for 2-level mean
transition utilities.Figure 2. Bland-Altman plot of 3L and matched 5L utilities (n =Discussion
In this study, we determined the utilities of the 2 adult ver-
sions of the EQ-5D health status questionnaire (3L and 5L) from
the perspective of the general population in Hungary. In accor-
dance with national HTA recommendations,6 our sample was
representative of the Hungarian general population for age and
sex. Up to now, only Poland (3L and 5L) and Slovenia (3L) in the
Central and Eastern European region have developed TTO-based
value sets.39–42 The present study overall marks a considerable
achievement in taking HTA to the next level in Hungary.
Furthermore, the study created a unique opportunity to compare
the characteristics of the 2 value sets derived from a common
sample and to analyze the impact of differences in wording of the
descriptive systems on changes in utilities.Figure 1. Kernel density plot of 3L, 5L, and matched 5L utilities.
3L indicates 3-level; 5L, 5-level.Both for the 3L and 5L, the Hungarian value sets are based on a
main effects model, because the EQ-VT design is optimized for
such models.25 For the 3L, model 1 (3L) and model 3 (3L) produced
inconsistent estimates for UA2 owing to heteroscedasticity being
present in data. Very likely the different study design of the 3L
valuation exercise, in particular, the smaller proportion of mild
states among the 30 (3L) states valued, resulted in a stronger
heteroscedasticity for the 3L. The 5L value set outperformed the 3L
in many ways, such as ceiling effects and the consistency of mean
transitions across the range of baseline utilities. Acknowledging
the limitations of the 3L descriptive system43–46 and the Hungary-
specific differences in wording, in future studies both in and
outside HTA, generally the 5L descriptive system and value set are
recommended to be used in Hungary. Nevertheless, the Hungarian
3L value set will be useful in many cases including clinical trials
administering the 3L, studies aiming to reanalyze previously
collected local 3L data, and conditions where the 3L is a more243). The horizontal line represents the mean of the differences
(d) between 3L and 5L utilities, while the 95% limits of agreement,
obtained as d 6 1.96 * SD of d, are indicated by dashed lines.
MO3/5 indicates most severe level of mobility; 3L, 3-level; 5L, 5-level.
1244 VALUE IN HEALTH SEPTEMBER 2020suitable instrument to assess quality of life (eg, where the
response level “confined to bed” (3L) is actually relevant for the
patient population).
This is the first study in Europe to derive cTTO-based value sets
of the 3L and 5L from a common sample. The 3L and 5L value sets
for Hungary are rather close to each other in many aspects
including the range of utilities and rank ordering of the 5 di-
mensions. Consistently with previous studies,14,25,34 changing the
wording of the most severe level of mobility was responsible for
the major differences seen between the 3L and 5L value sets. For
most 3L and matched 5L health state pairs in which the most
severe level of mobility was affected, a lower utility was demon-
strated for the 3L. Thus, the large positive impact of changing
“confined to bed” (3L) to “unable to walk” (5L) exceeded the
overall impact of smaller changes with more negative wording in
the other 4 dimensions. It appears that the overall impact of
“confined to bed” (3L) and whether it is attenuated by other di-
mensions will depend on the disease studied.
Differences in wording of the anxiety/depression dimension
slightly affected the utilities (“feeling down” [3L] vs “depressed”
[5L]). There seem to be 2 major reasons underlying this observa-
tion. First, only a part of a composite dimension is involved by this
wording change. Prior findings suggest that in valuation the
composite dimension of anxiety/depression is interpreted to mean
an average of anxiety and depression, but weighted more toward
anxiety.47 Secondly, anxiety/depression had a lower relative
importance in the ranking of dimensions in Hungary, thus its
impact on utilities was modest. It is plausible that in a country
where anxiety/depression is among the most important di-
mensions, the impact of such a change in wording would be re-
flected more markedly. Further research is warranted to
investigate how the differences in wording alter people’s ratings
on their own health.
The main limitations of our study are related to the valuation of
3L health states. First, each respondent valued only 3 3L health
states after the 5L, and not all respondents valued the pits state or
any mild state. Secondly, respondents were not informed that the
last 3 health states refer to a different descriptive system. The way
the respondents interpreted the 3L states may not have been how
they would have interpreted them if they had not seen 5L states
beforehand. Future studies may be conducted using different study
designs (eg, between-sample design or dropping levels 2 and 4 of
the 5L) to further explore the differences between the 3L and 5L in
the context of valuation. Thirdly, DCE data were not used in
developing the 5L value set, since the cTTO data alone resulted in a
fully consistent 5L model. Our choice was mainly motivated by
avoiding unnecessary conceptual and statistical assumptions.
Moreover, using an identical preference elicitation method to
develop 3L and 5L value sets is expected to ensure consistency
across HTA reports. Finally, we acknowledge that wording changes
in the 3L compared to other language versions detract from the aim
of methodological standardization of the EQ-5D at a supranational
level. In the past 2 decades, the 3L has been administered to over 25
000 people in nearly 50 clinical and population studies in
Hungary.8,48–50 Being aware of the substantial collection of Hun-
garian studies, we believe that a revision of the translation before
this valuation study would have caused more harm than good.Conclusion
This study developed Hungarian value sets of the EQ-5D 3L
and 5L questionnaires based on cTTO valuations from the
general population in Hungary. More similarities were noted
between the 2 value sets than in any previous study.Consistent with a similar study in the United States, the most
severe level of mobility appeared to be responsible for the
major differences seen between the 3L and 5L value sets. It is
hoped that the value sets will facilitate the uptake in the use
of EQ-5D in economic evaluations and the advancement of
HTA in Hungary. These findings contribute to the under-
standing of how the wording of descriptive systems affects
the estimates of utilities.Supplemental Material
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